Soleno completes enrollment in DCCR PWS study; triggers $10M capital infusion

SOLENO THERAPEUTICS INC

Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.
Top-line data expected Q3 2023; FDA previously acknowledged data could support an NDA submission.
Completion triggers $10 million capital infusion from Nantahala, Abingworth, and Vivo per Dec 2022 SPA.
77 patients enrolled at 17 US and 5 UK sites; 93% of total 83 patients participated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.